A phase 3 study of first-line pembrolizumab monotherapy with locally advanced or metastatic NSCLC found that patients with a PD-L1 tumor proportion score (TPS) of 50% or greater had the lowest hazard ratio for OS [10]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.